Compare Amphastar Pharmaceuticals Inc (AMPH) vs Five Below Inc (FIVE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Five Below Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Five Below Inc trades at $189.77 (market cap $10.47B). The key difference: Five Below Inc is far larger — about 12.7× Amphastar Pharmaceuticals Inc's market cap, and Five Below Inc is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | FIVE | |
|---|---|---|
Market Cap | $826.08M | $10.47B |
Sector | Health | Consumer Staples |
52-Week High | $30.81 | $247.71 |
52-Week Low | $16.87 | $129.46 |
Enterprise Value | $1.22B | $11.36B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
FIVE trades at $189.39, up 2.8% today, with a bearish technical signal but strong fundamentals including a 36.81% gross margin and 21.13% ROE. Recent earnings beats and a 60% analyst buy rating support momentum, while expansion to 2,000 stores (GlobeNewsWire, July 9, 2026) highlights growth. The stock faces resistance near $191 with net cash flow positive at $152 million in 2025.
Outlook remains positive with a $252.09 consensus target, though risks include margin pressure from 2025's 6.54% net margin and bearish moving averages. Growth drivers are digital marketing and store openings, but investor caution is warranted near technical resistance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Five Below Inc
Five Below is a value-oriented retailer that operated 1,190 stores in the United States as of the end of fiscal 2021. Catering to teen and preteen consumers, stores feature a wide variety of merchandise, the vast majority of which is priced below $6. The assortment focuses on discretionary items in several categories, particularly leisure (such as sporting goods, toys, and electronics
Read more on FIVE →
